Liquidia Corporation (LQDA) Reports $222.7M Q3 Sales, $389.7M Settlement Charge
Liquidia Corporation (LQDA) reported Q3 2026 sales of $222.7M, up 31% from Q2, and a net loss of $236.3M, including a $389.7M litigation settlement charge. Adjusted EBITDA rose to $140.5M, the fifth consecutive quarterly increase. The company agreed to pay $380.7M in settlement installments during 2026-2027. YUTREPIA sales grew sharply year-over-year, but the PH-ILD indication will be removed from the label.
How this was made
The 30-second read
Why it matters
The settlement charge creates near‑term earnings pressure but removes legal risk, which could be viewed positively over the longer term.
Market read
The disclosure is material for traders due to the large settlement and its effect on cash and earnings.
What to watch
Cash balance of $396.1M may support operations post‑settlement; sales momentum remains strong.
Background
Liquidia's Q3 update combines a 31% sales increase with a one‑time $389.7M settlement charge, impacting earnings and cash.
Ticker impact
Q3 2026 product sales of $222.7M and a $389.7M litigation settlement charge were disclosed for the first time.
likely downside as investors price in the $389.7M settlement liability
The settlement charge dwarfs the quarterly profit and reduces cash, outweighing the sales increase.
Market effects
Biotech sector may see heightened scrutiny of litigation risks.
U.S. biotech investors could adjust exposure to companies with pending settlements.
Limited to investors tracking US-listed biotech firms.
Counterpoint
The settlement clears legal uncertainty, potentially enabling future growth and partnerships.
Key entities
- companyLiquidia Corporation
US‑listed biotech firm reporting Q3 results and settlement.